348 related articles for article (PubMed ID: 37298342)
1. Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
Richter P; Cardoneanu A; Dima N; Bratoiu I; Rezus C; Burlui AM; Costin D; Macovei LA; Rezus E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298342
[TBL] [Abstract][Full Text] [Related]
2. [How do I treat interstitial lung disease in systemic sclerosis?].
Riemekasten G
Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
[TBL] [Abstract][Full Text] [Related]
3. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
[TBL] [Abstract][Full Text] [Related]
4. [Systemic sclerosis-related interstitial lung disease: Diagnostic and therapeutic strategy in the light of recent clinical trials].
Lescoat A; Jouneau S; Uzunhan Y; Jégo P; Cottin V; Hachulla E
Rev Med Interne; 2022 Jun; 43(6):365-374. PubMed ID: 35181160
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
6. The other connective tissue disease-associated interstitial lung diseases: Sjogren's syndrome, mixed connective tissue disease, and systemic lupus erythematosus.
Lee CT; Strek ME
Curr Opin Pulm Med; 2021 Sep; 27(5):388-395. PubMed ID: 34127620
[TBL] [Abstract][Full Text] [Related]
7. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus.
Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Takahashi T; Toyama T; Ichimura Y; Noda S; Akamata K; Miyazaki M; Kuwano Y; Yanaba K; Sato S
J Dermatol; 2014 May; 41(5):418-20. PubMed ID: 24801917
[TBL] [Abstract][Full Text] [Related]
8. Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus.
Moazedi-Fuerst FC; Kielhauser S; Brickmann K; Tripolt N; Meilinger M; Lufti A; Graninger W
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S87-91. PubMed ID: 25665185
[TBL] [Abstract][Full Text] [Related]
9. The Oral-Lung Microbiome Axis in Connective Tissue Disease-Related Interstitial Lung Disease.
Bongers KS; Massett A; O'Dwyer DN
Semin Respir Crit Care Med; 2024 Jun; 45(3):449-458. PubMed ID: 38626906
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of interstitial lung disease in systemic lupus erythematosus in France: A nation-wide population-based study over 10 years.
Mageau A; Borie R; Crestani B; Timsit JF; Papo T; Sacre K
Respirology; 2022 Aug; 27(8):630-634. PubMed ID: 35446457
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)].
Buschulte K; Hoffmann-Vold AM; Dobrota RD; Höger P; Krause A; Kreuter M
Z Rheumatol; 2021 Oct; 80(8):743-754. PubMed ID: 34505934
[TBL] [Abstract][Full Text] [Related]
13. Interstitial lung disease in connective tissue disorders.
Fischer A; du Bois R
Lancet; 2012 Aug; 380(9842):689-98. PubMed ID: 22901890
[TBL] [Abstract][Full Text] [Related]
14. The potential utility of anterior upper lobe honeycomb-like lesion in interstitial lung disease associated with connective tissue disease.
Yamakawa H; Ogura T; Sato S; Nishizawa T; Kawabe R; Oba T; Kato A; Horikoshi M; Akasaka K; Amano M; Kuwano K; Sasaki H; Baba T; Matsushima H
Respir Med; 2020 Oct; 172():106125. PubMed ID: 32911135
[TBL] [Abstract][Full Text] [Related]
15. Comparison of nintedanib-induced gastrointestinal adverse events between patients with systemic sclerosis-associated interstitial lung disease and idiopathic interstitial pneumonias.
Imai M; Okabayashi H; Akaike K; Hamada S; Masunaga A; Ichiyasu H; Sakagami T
Respir Investig; 2024 May; 62(3):317-321. PubMed ID: 38395006
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease.
Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M
Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595
[TBL] [Abstract][Full Text] [Related]
17. Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis.
Khanna SA; Nance JW; Suliman SA
Curr Rheumatol Rep; 2022 May; 24(5):166-173. PubMed ID: 35499699
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
Yamasaki Y; Kuwana M
Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the management of systemic sclerosis-associated interstitial lung disease.
Hoffmann-Vold AM; Distler O; Crestani B; Antoniou KM
Curr Opin Pulm Med; 2022 Sep; 28(5):441-447. PubMed ID: 35855572
[TBL] [Abstract][Full Text] [Related]
20. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease.
Higuero Sevilla JP; Memon A; Hinchcliff M
Arthritis Res Ther; 2023 Jul; 25(1):118. PubMed ID: 37422652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
